dm+d

23079006

Articles

Vincristine: Cytotoxic Drug Stability Monograph

15 December 2020Stability information is essential for the safe aseptic preparation of vincristine

Safety in Lactation: Vinca alkaloids and etoposide

21 September 2020Vinca alkaloids, whether used as monotherapy or in combination with other antineoplastics, are contra-indicated in breastfeeding because of their cytotoxic action on dividing cells and…
Search Articles

Refrigerated Storage

Vincristine sulphateHospira UK Ltd (part of Pfizer)

Hospira UK Ltd (part of Pfizer)
Vincristine sulphate
Injection (1mg/ml)

Contact Pfizer in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

12 October 2021
London MI Service

Lactation Safety Information

No
No published evidence of safety
Serious adverse effects reported in adults
5 March 2020

New Medicines

MarqiboDiffuse large B-cell lymphoma (DLBCL) - CD20 positive; aggressive – newly diagnosed in elderly patients (aged 61-80 years)

Information

Marqibo
New formulation
Spectrum
Spectrum

Development and Regulatory status

None
Phase III Clinical Trials
None
Dec 19According to its website, Acrotech is developing and commercialising innovative proprietary medications, starting with the US market. Development for the EU/UK seems unlikely at this time [7].

Category

A tubulin polymerisation inhibitor. The Optisome encapsulated formulation utilises sphingomyelin which is resistant to hydrolysis, prolongs the circulating life of liposomes and extends the duration of drug release.
11 February 2015The annual incidence of DLBCL is 5-6/100,000 (increasing from 0.3/100,000 in those aged 35-39 years to 26.6/100,000 in those aged 80-84 years). There are around 4,835 new cases of DLBCL per year in the UK, the majority of which are CD20-positive.
Diffuse large B-cell lymphoma (DLBCL) - CD20 positive; aggressive – newly diagnosed in elderly patients (aged 61-80 years)
liposomal formulation
Intravenous infusion